BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24608451)

  • 21. [Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].
    Absaliamova OV; Korshunov AG; Loshakov VA; Kobiakov GL; Golanov AV; Urakov SV; Amanov RD; Lichinitser MR
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (1):17-23; discussion 23-4. PubMed ID: 19507310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.
    Chamberlain MC; Born D
    J Neurooncol; 2015 Nov; 125(2):249-51. PubMed ID: 26341371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
    Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M; Fortin D; Tsanaclis AM; Drouin R
    Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
    Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization.
    Raghavan R; Balani J; Perry A; Margraf L; Vono MB; Cai DX; Wyatt RE; Rushing EJ; Bowers DC; Hynan LS; White CL
    J Neuropathol Exp Neurol; 2003 May; 62(5):530-7. PubMed ID: 12769192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of 1p/19q codeletion in oligodendroglioma-like areas of pilocytic astrocytomas.
    Frazer B; Kearney H; Cryan J; Beausang A; Brett F; Farrell MA; Buckley PG
    Clin Neuropathol; 2018; 37(4):182-185. PubMed ID: 29595124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.
    Khayal IS; Vandenberg SR; Smith KJ; Cloyd CP; Chang SM; Cha S; Nelson SJ; McKnight TR
    Neuro Oncol; 2011 Nov; 13(11):1192-201. PubMed ID: 21865401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
    Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
    Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy.
    Pandith AA; Zahoor W; Manzoor U; Nisar S; Guru FR; Naikoo NA; Aein QU; Baba SM; Bhat AR; Ganai F; Shah P
    Cancer Genet; 2023 Nov; 278-279():55-61. PubMed ID: 37625215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
    Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
    Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].
    Yao K; Duan Z; Hu Z; Bian Y; Qi X
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):663-7. PubMed ID: 25567591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma.
    Suh JH; Park CK; Park SH
    J Korean Med Sci; 2013 Apr; 28(4):593-601. PubMed ID: 23579442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.